The WHO provides global information on noncommunicable diseases (NCDs), including cardiovascular diseases, cancer, diabetes, and chronic respiratory diseases. Explore their data, reports, and prevention strategies: WHO NCDs.
The Mayo Clinic offers comprehensive information on various diseases and conditions, including chronic illnesses. Their website covers symptoms, causes, risk factors, treatments, and lifestyle recommendations.
The ADA is a leading organization for diabetes prevention, management, and cure. Their website provides information, resources, events, and ways to get involved in the fight against diabetes.
Learn about overweight and obesity, including causes, treatment, prevention, and lifestyle changes.
MedlinePlus offers information on defining adult overweight and obesity, healthy weight management, and related topics.
The Centers for Disease Control and Prevention (CDC) provides comprehensive information on chronic diseases, including prevention, management, and data. You can learn about the most common chronic conditions in America, risk factors, and how to prevent conditions like heart disease, diabetes, and cancer.
The AHA is a nonprofit organization dedicated to fighting heart disease and stroke.
Includes:
Includes:
Includes:
Includes:
Includes:
Includes:
Tirzepatide is a novel, dual receptor agonist that targets both GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors. Initially developed for the treatment of type 2 diabetes, it is marketed under the brand name Mounjarofor glycemic control and has shown significant promise for weight loss, where the brand name Zepbound is being used. Administered as a once-weekly subcutaneous injection, tirzepatide has been shown to improve glycemic parameters and induce substantial weight loss when combined with lifestyle changes.
It is sometimes referred to as a "twincretin" because of its simultaneous action on both the GLP-1 and GIP receptors.
Certain populations should exercise caution or avoid tirzepatide:
The side effects of tirzepatide are largely related to its gastrointestinal activity:
Clinical trial data have documented these adverse effects, which are generally transient and tend to diminish with continued treatment.
Tirzepatide’s mode of action is twofold:
This dual mechanism not only helps regulate blood sugar levels after meals but also reduces appetite, making it effective for both glycemic control and weight management.
Recent clinical studies have demonstrated robust results with tirzepatide. In trials:
These outcomes have fueled both enthusiasm for its metabolic benefits and ongoing research into its long-term safety and effectiveness.
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist. It was originally approved by the FDA in 2019 for the management of type 2 diabetes. Later, in June 2021, it gained approval under the brand name Wegovy for use as a weight-loss treatment. The drug works by mimicking the effects of the natural hormone GLP-1 to enhance insulin secretion, lower glucagon levels, and slow gastric emptying, thereby helping control blood sugar and appetite.
Each brand has specific FDA-approved indications, yet all rely on semaglutide’s core GLP-1 receptor agonist activity.
Certain conditions warrant caution or outright avoidance when considering semaglutide:
Clinical experience and trials have identified a range of gastrointestinal and other side effects associated with semaglutide. Notably:
These side effects are generally thought to result from its action on the gastrointestinal system, particularly its delaying effect on gastric emptying. While many patients experience mild to moderate symptoms, these percentages help set expectations for what might occur during treatment.
Semaglutide’s mechanism centers on its role as a GLP-1 receptor agonist:
This combination of effects supports its use in both blood sugar management and weight loss strategies by mimicking natural hormonal responses to food intake.
Numerous clinical studies have validated semaglutide’s efficacy. Research indicates that when used in conjunction with a reduced-calorie diet and increased physical activity, semaglutide significantly improves glycemic control in people with type 2 diabetes and can lead to meaningful weight reduction in individuals with obesity. The landmark trials that led to its FDA approvals have demonstrated that semaglutide not only results in better metabolic outcomes but also reduces the risks of major cardiovascular events in at-risk populations.
Understanding semaglutide’s dual role in treating type 2 diabetes and obesity prompts further discussion on integrating lifestyle modifications with pharmacotherapy.
Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that was initially approved for the management of type 2 diabetes in 2010 under the brand name Victoza. Its potential for weight loss was later recognized, leading to an FDA approval in 2014 for chronic weight management under the brand name Saxenda. By mimicking the naturally occurring GLP-1 hormone, liraglutide improves glucose-dependent insulin secretion, suppresses glucagon release, and slows gastric emptying—all of which lead to improved blood sugar control and reduced appetite.
Although both formulations contain liraglutide, the dosing regimens and approved indications differ between the two brands.
Liraglutide should be used with caution or avoided in certain situations:
The most common side effects associated with liraglutide include:
Liraglutide exerts its effects by acting as a GLP-1 receptor agonist:
These combined actions facilitate both better glycemic control and a reduction in body weight when used alongside diet and exercise.
Clinical studies have consistently demonstrated that liraglutide is effective in both improving glycemic control and inducing weight loss:
Contrave is an FDA-approved prescription medication used to help manage weight. It is indicated for adults with obesity (a body mass index [BMI] of ≥30) or overweight adults (BMI of ≥27) who also have at least one weight-related condition such as hypertension, type 2 diabetes, or high cholesterol. Unlike semaglutide—which is a GLP-1 agonist used for type 2 diabetes and later for weight management under the name Wegovy—Contrave uses a combination of two active ingredients: naltrexone and bupropion. The two components work together to address different aspects of appetite and reward pathways in the brain, helping to reduce food cravings and control appetite when used in combination with diet and exercise.
Unlike semaglutide’s alternate identity as Wegovy when used for weight loss, Contrave remains known by its brand name or its component names.
Contrave should not be used in the following circumstances:
The most commonly reported side effects with Contrave include:
While percentages differ from one study to another, nausea and headache are among the most common across clinical trials. (For comparison, semaglutide’s reported side effects in its trials also include nausea and gastrointestinal symptoms, but the incidence rates are specific to each drug’s profile).
Contrave works primarily on the central nervous system. Its two components have distinct yet complementary actions:
Together, these actions help patients adhere to dietary changes while reducing the impulses that can lead to overeating.
Clinical studies have indicated that when combined with lifestyle modifications—specifically diet and exercise—Contrave can lead to modest but significant weight loss in many patients. A common finding across trials is that patients on Contrave tend to lose more weight than those on placebo, although individual results can vary. Research continues to evaluate its long‐term benefits and overall impact on weight‐related health conditions. Patients are advised to work closely with their healthcare providers to monitor progress and manage any side effects during treatment.
Metformin is a well-established medication that falls under the biguanide class and has been the first-line treatment for type 2 diabetes since its FDA approval in 1994. Although it is primarily indicated for glycemic control in individuals with type 2 diabetes, many patients experience modest weight loss while on the medication. This weight reduction is not the primary intent of metformin; rather, it tends to occur as a secondary benefit, potentially related to appetite suppression and gastrointestinal side effects.
In clinical discussions and studies on metabolic benefits, metformin is referred to by its generic name or known under the various brand associations it carries.
Metformin is generally safe for most patients with type 2 diabetes; however, there are certain situations in which its use is not recommended:
Always consult with your healthcare provider before starting or stopping metformin, especially if there are any pre-existing conditions that might heighten the risk of adverse effects.
While metformin is largely well tolerated, its most common side effects include:
These side effects explain both its therapeutic impact on blood sugar and its ancillary effect on weight, as reduced appetite and GI upset may lead to lower caloric intake.
Metformin primarily functions by lowering hepatic glucose production (gluconeogenesis) while simultaneously increasing insulin sensitivity in peripheral tissues. The drug may also influence weight through several pathways:
These combined effects help regulate blood sugar levels, and in patients predisposed to weight gain, metformin often results in modest weight loss as a secondary benefit.
Clinical research on metformin has consistently shown that while it is effective for maintaining glycemic control in type 2 diabetes, it can also contribute to weight loss. For example:
Orlistat is a lipase inhibitor designed to aid weight loss. It works by blocking the absorption of dietary fats in the gastrointestinal tract, so that approximately 25%–30% of ingested fat is not absorbed and is subsequently excreted in the stool. Orlistat is typically prescribed for overweight or obese adults who need help managing their weight and is most effective when combined with a reduced-calorie, low-fat diet and increased physical activity.
Both formulations share the same active ingredient, but the dosing and available strength differ, with Xenical prescribed for individuals with a higher body mass index or specific weight-loss needs, and Alli being a consumer-accessible option for milder cases of overweight.
Orlistat should be used cautiously or avoided under certain circumstances:
The most commonly reported side effects of orlistat are gastrointestinal in nature, stemming from its mechanism of action:
These side effects are usually dose-dependent and can be minimized by adhering to a lower-fat diet throughout treatment.
Orlistat works locally in the gastrointestinal tract by inhibiting pancreatic and gastric lipases—enzymes responsible for breaking down dietary fats. Without sufficient enzymatic action, fats are not completely hydrolyzed into absorbable free fatty acids and monoglycerides. As a consequence:
This gastrointestinal mechanism makes orlistat distinct from medications that act centrally and it works best as part of a complete lifestyle modification program.
Clinical studies have validated orlistat’s role in weight management:
These findings support the use of orlistat as a complementary tool in combating obesity and its related metabolic complications.
Phentermine is a prescription medication approved by the FDA for short-term weight management. Typically used for up to 12 weeks, phentermine is intended for overweight or obese individuals, often in the context of a reduced-calorie diet and increased physical activity. It functions as an appetite suppressant that stimulates the central nervous system, leading to decreased hunger and reduced caloric intake. Phentermine’s chemical structure is similar to that of amphetamines, which contributes to its stimulant properties and controlled substance classification.
In many clinical settings and research discussions, phentermine is referenced by its generic name or one of its established brand names.
Phentermine should be avoided or used with caution in certain populations:
Common side effects associated with phentermine include:
Phentermine primarily works as a centrally acting stimulant:
These combined effects help reduce caloric intake and facilitate weight loss when used alongside lifestyle modifications.
Clinical studies evaluating phentermine have consistently shown that when combined with a reduced-calorie diet and increased physical activity, it can lead to significant short-term weight loss in overweight and obese individuals. Its efficacy in reducing appetite and accelerating weight loss is well documented; however, its use is generally limited by concerns over cardiovascular side effects and potential dependency. Consequently, phentermine is recommended for a limited duration (typically 12 weeks or less), and patients are closely monitored throughout treatment.
*DEA CONTROLLED MEDICATION: PRESCRIBING RESTRICTIONS APPLY*
Qsymia is a prescription weight-management medication approved for chronic weight loss in adults. It is a fixed-dose combination of two active ingredients: phentermine, a sympathomimetic amine that acts as an appetite suppressant, and topiramate extended release, an anticonvulsant that helps enhance satiety. Qsymia is indicated for adults with an initial body mass index (BMI) of 30 kg/m² or greater (obesity) or those with a BMI of 27 kg/m² or greater (overweight) who also have at least one weight-related medical condition (such as hypertension, type 2 diabetes, or high cholesterol). The medication is taken once daily and is intended to be used in conjunction with a reduced-calorie diet and increased physical activity.
Both active ingredients contribute synergistically to reduce hunger and caloric intake while supporting sustained weight loss when combined with lifestyle changes.
Certain conditions or situations warrant caution or complete avoidance of Qsymia:
Qsymia’s side effect profile is primarily linked to its individual components:
The side effects are generally dose-dependent and, for many patients, tend to diminish over the course of treatment. Adherence to the recommended dosing schedule—usually involving a slow titration phase—can help minimize adverse reactions.
Qsymia exerts its weight-loss effects through a dual mechanism:
Together, these actions help sustain a reduced appetite and support behavioral changes that lead to significant weight loss over time when combined with an appropriate diet and exercise program.
Clinical trials have demonstrated Qsymia’s effectiveness in weight management:
Such outcomes have provided the foundation for Qsymia’s approval and its use as a pharmacological adjunct to diet and exercise in obesity management.
*DEA CONTROLLED MEDICATION: PRESCRIBING RESTRICTIONS APPLY*
Topamax is an anticonvulsant medication that is FDA approved for the treatment of seizures and for migraine prevention. Although it is not specifically approved for weight loss, its use off-label for this purpose is common due to the consistent observation that patients tend to lose weight during therapy. In fact, when combined with phentermine (a stimulant appetite suppressant) in the FDA-approved formulation known as Qsymia, topiramate’s weight-reducing properties are leveraged for treating obesity.
Even when prescribed on its own for weight loss, topiramate is still referred to by its generic name, particularly in off-label settings.
Topiramate should be used with caution or avoided in certain situations:
The side effects associated with topiramate are well-documented, especially from its use in epilepsy and migraine prevention, and include:
For weight loss purposes, the appetite-suppressing effects that contribute to these side effects are also the factors believed to drive reduced caloric intake.
The exact mechanism by which topiramate induces weight loss is not fully understood, but several potential effects are recognized:
These effects combine to yield the modest yet meaningful reductions in body weight often observed during treatment, especially when paired with lifestyle modifications.
Multiple clinical studies have examined topiramate’s impact on body weight:
Such research underpins the rationale for using topiramate as a weight-loss tool, either alone (off-label) or as part of a combined therapy.
Naltrexone is a medication primarily approved for the treatment of opioid and alcohol use disorders. It functions as an opioid receptor antagonist, meaning it binds to opioid receptors in the brain without activating them, thereby blocking the euphoric and reinforcing effects of opioids. This same property has led researchers to explore naltrexone as a tool for weight loss—especially when combined with other medications, such as bupropion. In this dual-therapy approach (marketed as Contrave), naltrexone contributes to reducing cravings and curbing overeating by modulating the reward centers involved in eating behavior.
When discussed in obesity management, naltrexone is typically referenced as a component in combination products rather than as a single agent.
Naltrexone should not be used or should be used with extreme caution in certain populations:
The side effects associated with naltrexone, when used for addiction management, can be similar when it is applied in weight loss strategies:
When used as part of combination therapy (such as in Contrave), the overall side effect profile may also include those related to the companion medication (bupropion), which further aids in appetite suppression and mood regulation.
Naltrexone’s mechanism is centered on its action as an opioid receptor antagonist:
This mechanism provides a rationale for its use in weight loss—especially when the goal is to diminish the incentive to consume excess calories and manage binge eating patte.
Clinical studies have shed light on the role of naltrexone in weight management:
These studies help position naltrexone not as a stand-alone weight loss pill but as an adjunctive treatment in a broader weight management plan that includes lifestyle and dietary interventions.
Bupropion is an atypical antidepressant that was originally developed to treat major depressive disorder and seasonal affective disorder. It is also used as a smoking cessation aid under the brand name Zyban. One distinctive feature of bupropion is that, unlike many other antidepressants that are associated with weight gain, it is more commonly linked to weight loss or at least weight neutrality. In many clinical settings, people treated with bupropion experience reduced appetite and modest weight loss, a side effect that has contributed to its consideration in weight management, particularly when used as a component in combination therapies like Contrave (with naltrexone).
Each formulation has its approved indication, yet they all rely on bupropion’s unique mechanism of modulating dopamine and norepinephrine levels, which may also contribute to appetite suppression and energy regulation.
Bupropion should be used with caution or avoided altogether in certain situations:
The common side effects associated with bupropion include:
Because of its effect on neurotransmitters that regulate appetite and reward, the weight loss seen with bupropion is considered an ancillary benefit in many cases, although it is not marketed or prescribed solely for weight management.
Bupropion exerts its effects by influencing key neurotransmitters:
These combined actions underlie bupropion’s use in treating depression and aiding smoking cessation as well as its observed influence on weight when used in appropriate populations.
Clinical investigations have highlighted bupropion’s potential for weight loss:
While weight loss is viewed as a positive additional effect, bupropion is prescribed primarily for its mood-regulating properties and smoking cessation benefits, and its use in weight management is typically as part of a broader treatment plan.
Copyright © 2024 ICARENP- All Rights Reserved.
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.